... level of EGFR in cancer tissues is correlated with prognosis, but not with responsiveness to EGFR tyrosine kinase inhibitor treatment, suggesting that, independent of its kinase activity, EGFR may ...
... therapy beyond outgrowth of cells with BCR-ABL point mutations and support the use of other tyrosine kinase inhibitors to treat a broad spectrum of imatinib-resistant CML patients," the authors write. ...
... typically treated with the targeted therapy imatinib (Gleevec), a tyrosine kinase inhibitor.
“Gleevec does dramatically improve prognosis of CML patients,” notes Pandolfi. “But, ...
... growth factor receptor (EGFR) tyrosine kinase inhibitors, said Massimo Cristofanilli, M.D., the ... growth factor receptor (EGFR) tyrosine kinase inhibitors, to become commercially available. Iressa ...
... small-cell lung cancer, with oral EGFR inhibitors like erlotinib," said Prof. Rafael Rosell, ... lung cancer, and the first tangible target for customizing treatment with EGFR tyrosine kinase inhibitors." ...
... University of Hong Kong.
"Currently, gefitinib and other EGFR tyrosine kinase inhibitors are considered as second line therapy for advanced non-small-cell lung cancers, meaning that ...
... therapeutic strategy for pancreatic cancer has been developed. Erlotinib is a small molecule tyrosine kinase inhibitor that efficiently blocks EGFR. Preliminary results of phase III trial in ...
... as a giant molecular machine, with each part in close communication with the others.
"It is clear that tyrosine kinase inhibitors do not simply inhibit the enzyme, but rather remodel the machine," ...
... class of anti-cancer drugs known as EGFR tyrosine kinase inhibitors (TKI) to become commercially available after two Phase II trials found the drug to be efficacious. Iressa was ...
... future design and implementation of targeted cancer therapies. Small molecule tyrosine kinase inhibitors, such as imatinib (Gleevec) which targets the BCR-ABL kinase associated with chronic myeloid ...
... ; Sorafenib and Everolimus can be recommended as second-line therapy after cytokine and tyrosine kinase inhibitor (TKI) failure, respectively.
The expectation is that further targeted agents will be ...
... be 300,000. While there are a number of licensed drugs, collectively known as tyrosine kinase inhibitors (TKIs), which are very effective in treating CML, they must be administered daily for the rest ...
... this protein have been historically resistant to imatinib and also to second-generation tyrosine kinase inhibitors, including dasatinib, nilotinib and bosutinib.
The autophagy process allows stem ...
... (deletion in exon 19, missense L858R) are the most important predictors of sensitivity to tyrosine-kinase inhibitor targeted therapies (Italy)
Barbara Zolty from the World Health Organization (WHO) ...
... cell renal cell cancer, including papillary renal cancer, don't respond as well to tyrosine kinase inhibitors, such as sunitinib and sorafenib, as patients with clear cell renal cell. ...
